Can Specialized Pro-resolving Mediators Deliver Benefit Originally Expected from Fish Oil?

Martin D. Rosenthal, Jayshil Patel, Kyle Staton, Robert Martindale, Frederick A. Moore, Gilbert R. Upchurch

Research output: Contribution to journalReview article

Abstract

Purpose of the Review: Fish oil (FO) supplementation has historically been used by individuals suffering from cardiovascular disease and other inflammatory processes. However, a meta-analysis of several large randomized control trials (RCTs) suggested FO conferred no benefit in reducing cardiovascular risk. Skeptics surmised that the lack of benefit was related to FO dose or drug interactions; therefore, the widely accepted practice of FO consumption was brought into question. Recent Findings: Thereafter, Serhan et al. identified specialized pro-resolving mediators (SPMs) to be one of the bioactive components and mechanisms of action of FO. SPMs are thought to enhance resolution of inflammation, as opposed to classic anti-inflammatory agents which inhibit inflammatory pathways. Numerous diseases, including persistent Inflammation, immunosuppression, and catabolic syndrome (PICS), are rooted in a burden of chronic inflammation. SPMs are gaining traction as potential therapeutic agents used to resolve inflammation in cardiovascular disorders, inflammatory bowel disease, sepsis, pancreatitis, and acute respiratory distress syndrome (ARDS). Summary: This narrative reviews the history of FO and the various studies that made the health benefits of FO inconclusive, as well as an overview of SPMs and their use in specific disease states.

Original languageEnglish (US)
Article number40
JournalCurrent Gastroenterology Reports
Volume20
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Fish Oils
Inflammation
Adult Respiratory Distress Syndrome
Traction
Insurance Benefits
Drug Interactions
Inflammatory Bowel Diseases
Pancreatitis
Immunosuppression
Meta-Analysis
Sepsis
Anti-Inflammatory Agents
Cardiovascular Diseases
History

Keywords

  • Fish oil
  • Inflammation
  • Omega-3 fatty acids
  • Persistent immunosuppression inflammation catabolic syndrome (PICS)
  • Specialized pro-resolving mediators

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Can Specialized Pro-resolving Mediators Deliver Benefit Originally Expected from Fish Oil? / Rosenthal, Martin D.; Patel, Jayshil; Staton, Kyle; Martindale, Robert; Moore, Frederick A.; Upchurch, Gilbert R.

In: Current Gastroenterology Reports, Vol. 20, No. 9, 40, 01.09.2018.

Research output: Contribution to journalReview article

Rosenthal, Martin D. ; Patel, Jayshil ; Staton, Kyle ; Martindale, Robert ; Moore, Frederick A. ; Upchurch, Gilbert R. / Can Specialized Pro-resolving Mediators Deliver Benefit Originally Expected from Fish Oil?. In: Current Gastroenterology Reports. 2018 ; Vol. 20, No. 9.
@article{ab6060bfda8a492c8b135b255ba45e12,
title = "Can Specialized Pro-resolving Mediators Deliver Benefit Originally Expected from Fish Oil?",
abstract = "Purpose of the Review: Fish oil (FO) supplementation has historically been used by individuals suffering from cardiovascular disease and other inflammatory processes. However, a meta-analysis of several large randomized control trials (RCTs) suggested FO conferred no benefit in reducing cardiovascular risk. Skeptics surmised that the lack of benefit was related to FO dose or drug interactions; therefore, the widely accepted practice of FO consumption was brought into question. Recent Findings: Thereafter, Serhan et al. identified specialized pro-resolving mediators (SPMs) to be one of the bioactive components and mechanisms of action of FO. SPMs are thought to enhance resolution of inflammation, as opposed to classic anti-inflammatory agents which inhibit inflammatory pathways. Numerous diseases, including persistent Inflammation, immunosuppression, and catabolic syndrome (PICS), are rooted in a burden of chronic inflammation. SPMs are gaining traction as potential therapeutic agents used to resolve inflammation in cardiovascular disorders, inflammatory bowel disease, sepsis, pancreatitis, and acute respiratory distress syndrome (ARDS). Summary: This narrative reviews the history of FO and the various studies that made the health benefits of FO inconclusive, as well as an overview of SPMs and their use in specific disease states.",
keywords = "Fish oil, Inflammation, Omega-3 fatty acids, Persistent immunosuppression inflammation catabolic syndrome (PICS), Specialized pro-resolving mediators",
author = "Rosenthal, {Martin D.} and Jayshil Patel and Kyle Staton and Robert Martindale and Moore, {Frederick A.} and Upchurch, {Gilbert R.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1007/s11894-018-0647-4",
language = "English (US)",
volume = "20",
journal = "Current Gastroenterology Reports",
issn = "1522-8037",
publisher = "Current Medicine Group",
number = "9",

}

TY - JOUR

T1 - Can Specialized Pro-resolving Mediators Deliver Benefit Originally Expected from Fish Oil?

AU - Rosenthal, Martin D.

AU - Patel, Jayshil

AU - Staton, Kyle

AU - Martindale, Robert

AU - Moore, Frederick A.

AU - Upchurch, Gilbert R.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Purpose of the Review: Fish oil (FO) supplementation has historically been used by individuals suffering from cardiovascular disease and other inflammatory processes. However, a meta-analysis of several large randomized control trials (RCTs) suggested FO conferred no benefit in reducing cardiovascular risk. Skeptics surmised that the lack of benefit was related to FO dose or drug interactions; therefore, the widely accepted practice of FO consumption was brought into question. Recent Findings: Thereafter, Serhan et al. identified specialized pro-resolving mediators (SPMs) to be one of the bioactive components and mechanisms of action of FO. SPMs are thought to enhance resolution of inflammation, as opposed to classic anti-inflammatory agents which inhibit inflammatory pathways. Numerous diseases, including persistent Inflammation, immunosuppression, and catabolic syndrome (PICS), are rooted in a burden of chronic inflammation. SPMs are gaining traction as potential therapeutic agents used to resolve inflammation in cardiovascular disorders, inflammatory bowel disease, sepsis, pancreatitis, and acute respiratory distress syndrome (ARDS). Summary: This narrative reviews the history of FO and the various studies that made the health benefits of FO inconclusive, as well as an overview of SPMs and their use in specific disease states.

AB - Purpose of the Review: Fish oil (FO) supplementation has historically been used by individuals suffering from cardiovascular disease and other inflammatory processes. However, a meta-analysis of several large randomized control trials (RCTs) suggested FO conferred no benefit in reducing cardiovascular risk. Skeptics surmised that the lack of benefit was related to FO dose or drug interactions; therefore, the widely accepted practice of FO consumption was brought into question. Recent Findings: Thereafter, Serhan et al. identified specialized pro-resolving mediators (SPMs) to be one of the bioactive components and mechanisms of action of FO. SPMs are thought to enhance resolution of inflammation, as opposed to classic anti-inflammatory agents which inhibit inflammatory pathways. Numerous diseases, including persistent Inflammation, immunosuppression, and catabolic syndrome (PICS), are rooted in a burden of chronic inflammation. SPMs are gaining traction as potential therapeutic agents used to resolve inflammation in cardiovascular disorders, inflammatory bowel disease, sepsis, pancreatitis, and acute respiratory distress syndrome (ARDS). Summary: This narrative reviews the history of FO and the various studies that made the health benefits of FO inconclusive, as well as an overview of SPMs and their use in specific disease states.

KW - Fish oil

KW - Inflammation

KW - Omega-3 fatty acids

KW - Persistent immunosuppression inflammation catabolic syndrome (PICS)

KW - Specialized pro-resolving mediators

UR - http://www.scopus.com/inward/record.url?scp=85051140000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051140000&partnerID=8YFLogxK

U2 - 10.1007/s11894-018-0647-4

DO - 10.1007/s11894-018-0647-4

M3 - Review article

VL - 20

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

SN - 1522-8037

IS - 9

M1 - 40

ER -